B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Wednesday, November 13th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.41) per share for the quarter. B. Riley has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune's FY2025 earnings at $0.73 EPS.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. During the same quarter last year, the company earned ($0.39) earnings per share.

Several other analysts have also recently commented on the company. UBS Group initiated coverage on Altimmune in a report on Tuesday. They set a "buy" rating and a $26.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday. Finally, Evercore ISI raised shares of Altimmune to a "strong-buy" rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $20.00.

Altimmune Stock Performance

Altimmune stock traded down $1.07 during trading hours on Thursday, hitting $8.45. 5,132,622 shares of the stock were exchanged, compared to its average volume of 3,864,847. The business's 50-day moving average is $6.95 and its two-hundred day moving average is $6.89. Altimmune has a 12 month low of $2.34 and a 12 month high of $14.84. The stock has a market capitalization of $600.55 million, a P/E ratio of -5.45 and a beta of 0.09.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now directly owns 41,958 shares of the company's stock, valued at approximately $289,510.20. This represents a 27.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its holdings in Altimmune by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company's stock worth $156,000 after purchasing an additional 1,821 shares during the last quarter. Creative Planning lifted its holdings in shares of Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company's stock worth $113,000 after buying an additional 3,132 shares in the last quarter. CANADA LIFE ASSURANCE Co bought a new stake in shares of Altimmune in the first quarter valued at about $44,000. Charles Schwab Investment Management Inc. grew its stake in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock valued at $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC bought a new position in Altimmune during the third quarter worth about $31,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.